Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 10/20 | 0.73 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.58 |
| ▸ | HTR3B | O95264 | 4/20 | 0.58 |
| ▸ | HTR3A | P46098 | 4/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533600 | 0.93 | ADRB1 (0.65) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL30609706 | 0.87 | ADRB1 (0.71) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL1186816 | 0.87 | ADRB1 (0.71) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL1639578 | 0.86 | ADRB1 (0.69) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL232689 | 0.85 | ADRB1 (1.00) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL221254 | 0.85 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL2959681 | 0.83 | ADRB1 (0.96) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| Piperazine SCHEMBL28293494 | 0.83 | ADRB1 (0.96) | ADRB1CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL8264511 | 0.82 | MAPT (0.68) | ADRB1TP53ALDH1A1MAPTGFER | |
| SCHEMBL11528433 | 0.81 | ADRB1 (0.62) | ADRB1CHRNB2CHRNA4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2020210377-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210383-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2019-10-31 | — | — | US | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | VALO EARLY DISCOVERY, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9555039-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | FORMA TM, LLC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-7786129-B2 | Piperazine derivatives of dialkyl oxindoles | EGIS GYOGYSZERGYAR NYRT (HU) | 2010-08-31 | — | — | US | disclosed |
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070232619-A1 | Piperazine Derivatives of Dialkyl Oxindoles | EGIS GYOGYSZERGYAR RT. (HU) | 2007-10-04 | — | — | US | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
| CN-1993324-A | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-07-04 | — | — | CN | disclosed |
| EP-1776339-A2 | 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS Gyógyszergyár Nyrt (HU) | 2007-04-25 | — | — | EP | disclosed |
| WO-2005109987-A9 | 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-03-29 | — | — | WO | disclosed |
| WO-2005109987-A2 | 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-24 | — | — | WO | disclosed |
| EP-1597264-A2 | ANTIPARASITIC TERPENE ALKALOIDS | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072086-A2 | ANTIPARASITIC TERPENE ALKALOIDS | PFIZER LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185101-A1 | Antiparasitic terpene alkaloids | CYP51A1, DHPS, CYP8B1 | ADRB1 406/4885CHRNB2 607/4885CHRNA4 103/4885 |
| US-20070232619-A1 | Piperazine Derivatives of Dialkyl Oxindoles | TPH2, DRD3, CNR2 | ADRB1 203/4885CHRNB2 1298/4885CHRNA4 1530/4885 |
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | NFATC1, EP300, CD69 | ADRB1 3390/4885CHRNB2 3202/4885CHRNA4 2208/4885 |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FASN, IL1RN, CCR1 | ADRB1 2765/4885CHRNB2 4314/4885CHRNA4 4513/4885 |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | NAMPT, NAPRT, NNMT | ADRB1 1802/4885CHRNB2 2611/4885CHRNA4 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.